MedTrace Logo

Simultaneous Integrated Boost Radiotherapy and Concurrent Chemotherapy for Locally Advanced Esophageal Carcinoma

NCT02429622 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2017-01-18

No results posted yet for this study

Summary

This phase Ⅰ/Ⅱ trial is designed to explore a higher radiation dose by using IMRT simultaneous integrated boost technique with or without concurrent chemotherapy for locally advanced esophageal carcinoma.

Conditions

  • Esophageal Neoplasms

Interventions

RADIATION

IMRT simultaneous integrated boost

To achieve a prophylactic dosage and radical dosage once respectively

DRUG

Paclitaxel

Paclitaxel from 45 to 60 mg/m2 per week concurrent with radiotherapy for 5weeks

DRUG

Nedaplatin

Nedaplatin 25mg/m2 per week concurrent with radiotherapy for 5weeks

PROCEDURE

Esophagectomy

Radical esophagectomy 4-6 weeks after neoadjuvant therapy

Sponsors & Collaborators

  • Chinese Academy of Medical Sciences

    lead OTHER

Principal Investigators

  • Zefen Xiao, MD · The Department of Radiation Oncology ,Cancer Institute & Hospital，Chinese Academy of Medical Science

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
72 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2016-10-31
Completion
2016-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02429622 on ClinicalTrials.gov